Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT ID: NCT00035997
Last Updated: 2009-11-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
261 participants
INTERVENTIONAL
2002-04-30
2004-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This prospective, open-label, single arm, multicenter study will enroll approximately 200 prostate cancer patients with a history of at least one documented bone lesion documented by bone scan or radiograph. Patients must already be receiving hormone therapy and meet the following additional criteria:
* 18 years of age or older
* Histologically confirmed diagnoses of prostate cancer
* Confirmed objective evidence of metastatic bone disease as evidenced by bone scan or radiograph
* Received or will receive hormonal treatment also know as androgen deprivation therapy with an LHRH agonist or other hormonal treatments
Throughout the course of this 12-month trial, patients will be identified based on the duration of established hormonal treatment at the time of enrollment. Each patients duration of participation will be up to 56 weeks including a 4 week screening, 48 week treatment and a 4 week follow up.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zometa
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years
* Histologically confirmed diagnosis of carcinoma of the prostate
* Objective evidence of metastatic disease to the bone as evidenced by bone scan or radiograph at any point since their diagnosis of prostate cancer
* Currently receiving, or will begin receiving, hormonal therapy with an LHRH agonist or other hormonal treatments for either \< 6 months or \> 6 months
* ECOG performance status of 0, 1, or 2
Exclusion Criteria
* Patients who are hormone refractory typically defined as two or three consecutive increases in PSA measured at least one month apart while on hormone therapy
* Patients who are not treated with LHRH agonist or other hormonal treatments
* Patients who are currently receiving diethylstilbestrol (DES) or PC-SPES
* Patients with another nonmalignant disease which would confound the evaluation of primary endpoints or prevent the patient complying with the protocol.
* Patients with abnormal renal function as evidenced by either a serum creatinine greater than 2 mg/dL or by a calculated creatinine clearance of 60 ml/minute or less
* Corrected (adjusted for serum albumin) serum calcium concentration \< 8.0 mg/dl (2.00 mmol/L)
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Novartis Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scott L. Pescatore, PharmD.
Role: STUDY_DIRECTOR
Novartis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Norwood Clinic
Birmingham, Alabama, United States
Alaska Clinical Research Center, LLC
Anchorage, Alaska, United States
Advanced Urology Medical Center
Anaheim, California, United States
Urology Associates of Central CA
Fresno, California, United States
Center for Urological Research
La Mesa, California, United States
Atlantic Urological Medical Group
Long Beach, California, United States
Advanced Urology Medical Offices
Los Angeles, California, United States
Advanced Urology Medical Office
Los Angeles, California, United States
Boulder Medical Center
Boulder, Colorado, United States
Urology Associates, P.C.
Denver, Colorado, United States
Atlantic Urological Associates
Daytona Beach, Florida, United States
Southwest Florida Urologic Association
Fort Myers, Florida, United States
Diagnostic Clinic
Largo, Florida, United States
DMI Health Care Group, Inc.
Largo, Florida, United States
Marvin Stein, MD
Margate, Florida, United States
Miami Cancer Institute
Miami, Florida, United States
Advanced Research Institute
New Port Richey, Florida, United States
Florida Foundation for Healthcare Research
Ocala, Florida, United States
Urology Associates of Northeast Florida, PA
Orange Park, Florida, United States
Winter Park Urology Associates
Orlando, Florida, United States
Pinellas Urology, Inc.
St. Petersburg, Florida, United States
Southeastern Urological Center
Tallahassee, Florida, United States
Georgia Urology Research Institute
Atlanta, Georgia, United States
Ball Memorial Hospital
Muncie, Indiana, United States
Urological Associates PC
Davenport, Iowa, United States
Drs. Werner, Murdock and Francis PA Urology Associates
Greenbelt, Maryland, United States
Urology Associates of Middlesex County, Inc.
Marlborough, Massachusetts, United States
Lakeside Urology, P.C.
Saint Joseph, Michigan, United States
Millennium Medical Center
Southfield, Michigan, United States
Kansas City Urology Care
Kansas City, Missouri, United States
The Prostate Center of Greater St. Louis
St Louis, Missouri, United States
American Academy of Urology
Las Vegas, Nevada, United States
Urological Surgical Associates
Edison, New Jersey, United States
UroResearch, LLC
Morristown, New Jersey, United States
Shaukat M. Qureshi, MD
Pennsville, New Jersey, United States
Urology Associates
Stratford, New Jersey, United States
Associates in Urology, LLC
West Orange, New Jersey, United States
AccuMed Research Associates
Garden City, New York, United States
Urological Surgeons of Long Island PC
Garden City, New York, United States
Kingston Urological Assoc.
Kingston, New York, United States
Cary Urology, P.A.
Cary, North Carolina, United States
Matrix Research, LLC
Greenville, North Carolina, United States
The Urology Group
Cincinnati, Ohio, United States
Southwest Urology
Parma, Ohio, United States
Roger N. Andrews, MD Inc.
Arcadia, Pennsylvania, United States
Urologic Surgery, PC
Bala-Cynwyd, Pennsylvania, United States
James W. Thompson, MD Ltd.
Bryn Mawr, Pennsylvania, United States
Urology Institute of Pittsburgh
Monroeville, Pennsylvania, United States
Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States
Center for Urologic Care of Berks County
West Reading, Pennsylvania, United States
Grand Strand Urology
Myrtle Beach, South Carolina, United States
Urology Center of the South P.C.
Germantown, Tennessee, United States
Murfreesboro Medical Clinic
Murfreesboro, Tennessee, United States
Urology Associates, PA
Nashville, Tennessee, United States
Research Across America
Carrollton, Texas, United States
CAMC Clinical Trials
Charleston, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
US24
Identifier Type: -
Identifier Source: secondary_id
CZOL446EUS24
Identifier Type: -
Identifier Source: org_study_id